ClinicalTrials.gg
RecruitingNCT03588286PROTECT-ICDUpdated May 7, 2024

Programmed Ventricular Stimulation to Risk Stratify for Early Cardioverter-Defibrillator (ICD) Implantation to Prevent Tachyarrhythmias Following Acute Myocardial Infarction (PROTECT-ICD)

An interventional study of Electrophysiology study (EPS) and Standard Care in Sudden Cardiac Death, sponsored by Western Sydney Local Health District. Recruiting at 52 sites in 15 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2024-05-07.

Sponsored by Western Sydney Local Health District · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Registered 4 years 4 months after the study started (first participant enrolled Feb 2014, registered Jul 2018).
  • Started Feb 2014; still recruiting 12 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,058
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Study summary

The PROTECT-ICD trial is a physician-led, multi-centre randomised controlled trial targeting prevention of sudden cardiac death in patients who have poor cardiac function following a myocardial infarct (MI). The trial aims to assess the role of electrophysiology study (EPS) in guiding implantable cardioverter-defibrillator (ICD) implantation, in patients early following MI (first 40 days). The secondary aim is to assess the utility of cardiac MRI (CMR) in analysing cardiac function and viability as well as predicting inducible and spontaneous ventricular tachyarrhythmia when performed early post MI.

Following a MI patients are at high risk of sudden cardiac death (SCD). The risk is highest in the first 40 days; however, current guidelines exclude patients from receiving an ICD during this time. This limitation is based largely on a single study, The Defibrillator in Acute Myocardial Infarction Trial (DINAMIT), which failed to demonstrate a benefit of early ICD implantation. However, this study was underpowered and used non-invasive tests to identify patients at high risk. EPS identifies patients with the substrate for re-entrant tachyarrhythmia, and has been found in multiple studies to predict patients at risk of SCD. Contrast-enhanced CMR is a non-invasive test without radiation exposure which can be used to assess left ventricular function. In addition, it provides information on myocardial viability, scar size and tissue heterogeneity. It has an emerging role as a predictor of mortality and spontaneous ventricular arrhythmia in patients with a previous MI.

A total of 1,058 patients who are at high risk of SCD based on poor cardiac function (left ventricular ejection fraction (LVEF) ≤40%) following a ST-elevation or non-STE myocardial infarct will be enrolled in the trial. Patients will be randomised 1:1 to either the intervention or control arm.

In the intervention arm all patients undergo early EPS. Patients with a positive study (inducible ventricular tachycardia cycle length ≥200ms) receive an ICD, while patients with a negative study (inducible ventricular fibrillation or no inducible VT) are discharged without an ICD, regardless of the LVEF.

In the control arm patients are treated according to standard local practice. This involves early discharge and repeat assessment of cardiac function after 40 days or after 90 days following revascularisation (PCI or CABG). ICD implantation after 40 days according to current guidelines (LVEF≤30%, or ≤35% with New York Heart Association (NYHA) class II/III symptoms) could be considered, if part of local standard practice, however the ICD is not funded by the trial.

A proportion of trial patients from both the intervention and control arms at >48 hours following MI will undergo CMR to enable correlation with (1) inducible VT at EPS and (2) SCD and non-fatal arrhythmia on follow up. It will be used to simultaneously assess left ventricular function, ventricular strain, myocardial infarction size, and peri-infarction injury. The size of the infarct core, infarct gray zone (as a measure of tissue heterogeneity) and total infarct size will be quantified for each patient.

All patients will be followed for 2 years with a combined primary endpoint of non-fatal arrhythmia and SCD. Non-fatal arrhythmia includes resuscitated cardiac arrest, sustained ventricular tachycardia (VT) and ventricular fibrillation (VF) in participants without an ICD. Secondary endpoints will include all-cause mortality, non-sudden cardiovascular death, non-fatal repeat MI, heart failure and inappropriate ICD denial. Secondary endpoints for CMR correlation will include (1) the presence or absence of inducible VT at EP study, and (2) combined endpoint of appropriate ICD activation or SCD at follow up.

It is anticipated that the intervention arm will reduce the primary endpoint as a result of prevention of a) early sudden cardiac deaths/cardiac arrest, and b) sudden cardiac death/cardiac arrest in patients with a LVEF of 31-40%. It is expected that the 2-year primary endpoint rate will be reduced from 6.7% in the control arm to 2.8% in the intervention arm with a relative risk reduction (RRR) of 68%. A two-group chi-squared test with a 0.05 two-sided significance level will have 80% power to detect the difference between a Group 1 proportion of 0.028 experiencing the primary endpoint and a Group 2 proportion of 0.067 experiencing the primary endpoint when the sample size in each group is 470. Assuming 1% crossover and 10% loss to follow up the required sample size is 1,058 (n=529 patients per arm). To test the hypothesis that tissue heterogeneity at CMR predicts both inducible and spontaneous ventricular tachyarrhythmias will require a sample size of 400 patients to undergo CMR.

It is anticipated that the use of EPS will select a group of patients who will benefit from an ICD soon after a MI. This has the potential to change clinical guidelines and save a large number of lives.

02

Conditions studied

  • Sudden Cardiac Death

Keywords

  • Myocardial Infarction (MI), Sudden Cardiac Death (SCD), Electrophysiological Study (EPS), Ventricular Tachycardia (VT)
03

In context

Death, Sudden, Cardiac

364 studies on the registry are indexed under Death, Sudden, Cardiac; 84 are open to participants now.

This study's planned enrollment of 1,058 is above the median of 126 across 135 interventional studies indexed under Death, Sudden, Cardiac.

Browse Death, Sudden, Cardiac studies →

Lead sponsor

Western Sydney Local Health District is the lead sponsor of 36 studies on the registry; 18 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 2-40 days (inclusive) following a myocardial infarct
  • Impaired left ventricular systolic function (≤40% or at least moderately impaired)

Exclusion criteria

Exclusion Criteria:

  1. Age \<18 or >85;
  2. Pregnancy;
  3. Nursing home resident dependent on one or more activities of daily living;
  4. Significant non-cardiac co-morbidity with high likelihood of death within 1 year (this would include any , or other terminal disease);
  5. Significant psychiatric illnesses that may be aggravated by device implantation or that may preclude regular follow up;
  6. Intravenous drug abuse (ongoing);
  7. Unresolved infection associated with risk for hematogenous seeding;
  8. Pre-existing implantable cardioverter-defibrillator (ICD);
  9. Secondary prevention indication for an ICD (i.e. sustained ventricular arrhythmias occurring more than 48 hours after qualifying myocardial infarction (patients with ventricular arrhythmias occurring ≤48 hours of myocardial infarction, or with non-sustained ventricular tachycardia at any time, are not excluded));
  10. On the heart transplant list;
  11. Recurrent unstable angina despite revascularisation (defined as ongoing chest pain or ischemic symptoms at rest or with minimal exertion despite adequate treatment with anti-anginal medications);**
  12. Congestive heart failure class IV, defined as shortness of breath at rest, which is to medical treatment (not responding to treatment)** **NOTE: patients who meet exclusion based on (11) or (12) can be reviewed again in 2-3 days and if symptoms have resolved or treatment performed can be re-considered for inclusion.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
1,058 participants (estimated)

Study arms

  • Experimental
    Intervention Arm (Early EPS)

    The intervention group all undergo electrophysiologic study early after myocardial infarction (within 40 days of MI). If the study is positive (inducible monomorphic ventricular tachycardia of cycle length greater than or equal to 200ms) participants have an ICD implanted. Participants with a negative study (no inducible arrhythmia or induced ventricular fibrillation/ ventricular flutter cycle length \<200ms) are discharged without an ICD. A proportion of trial patients from both the intervention and control arms at \>48 hours following revascularisation for STEMI will undergo CMR to enable correlation with (1) inducible VT at EPS and (2) SCD and non-fatal arrhythmia on follow up. CMR will simultaneously assess left ventricular function, ventricular strain, myocardial infarction size, and peri-infarction injury.

    Procedure: Electrophysiology study (EPS) · Procedure: Cardiac Magnetic Resonance (CMR)

  • Active comparator
    Control Arm (Standard Care)

    The control group receive ongoing standard care according to the practise of their institution. This includes discharge from hospital as per their treating physician and follow up as usual in the community. Participants in this group would be eligible to receive an ICD according to the standard practise of their cardiologist (guideline recommendations are after 40 days following myocardial infarction or 90 days following revascularisation only in patients with left ventricular ejection fraction less than or equal to 30% or less than or equal to 35% in the presence of heart failure). A proportion of trial patients from both the intervention and control arms at \>48 hours following revascularisation for STEMI will undergo CMR to enable correlation with (1) inducible VT at EPS and (2) SCD and non-fatal arrhythmia on follow up. CMR will simultaneously assess left ventricular function, ventricular strain, myocardial infarction size, and peri-infarction injury.

    Other: Standard Care · Procedure: Cardiac Magnetic Resonance (CMR)

Interventions

  • ProcedureElectrophysiology study (EPS)

    EPS will be performed in all patients in the intervention arm with programmed ventricular stimulation with a drive train of 8 beats at 400 ms with up to 4 extrastimuli and stimulation from the right ventricular apex with current delivered at twice pacing threshold. The end point for stimulation will be sustained monomorphic ventricular tachycardia (VT) lasting \> 10 seconds. If sustained monomorphic VT with cycle length (CL) ≥200ms is induced by ≤4 extra stimuli the EPS result will be considered positive for inducible VT.30 Ventricular fibrillation or flutter with CL\<200ms will be considered a negative result. The Programmed Ventricular Stimulation (PVS) induction will be repeated a second time if the initial induction was negative for VT.

  • OtherStandard Care

    The control group receive ongoing standard care according to the practise of their institution. This includes discharge from hospital as per their treating physician and follow up as usual in the community. Participants in this group would be eligible to receive an ICD according to the standard practise of their cardiologist (guideline recommendations are after 40 days following myocardial infarction or 90 days following revascularisation only in patients with left ventricular ejection fraction less than or equal to 30% or less than or equal to 35% in the presence of heart failure).

  • ProcedureCardiac Magnetic Resonance (CMR)

    CMR will be performed on either a 1.5-T or 3-T scanner. Gadolinium contrast (Gd-BOPTA, MultihanceTM) will be administered for quantification myocardial perfusion imaging with subsequent late gadolinium enhanced imaging after a total dose of 0.1mmol/kg. Exclusion criteria specific for CMR will include pregnancy, renal insufficiency defined as glomerular filtration rate (GFR) \<30 mL/min, contraindication to MRI (including non-MRI compatible pacemaker/ICD or metal implants, non-MR safe prosthetic heart valves), claustrophobia which cannot be controlled via standard methods (benzodiazepines and/or sedative antihistamine administration) and prior allergic reaction to gadolinium-based contrast agent.

06

What researchers measure

Primary outcomes

  1. Sudden cardiac death

    Cause of death will be determined based on information obtained from witnesses, family members, death certificates, hospital records and autopsy or coroner reports. Sudden cardiac death will be explicitly defined as death that occurs "suddenly and unexpectedly" in a patient in otherwise stable condition and includes witnessed instantaneous deaths (with or without documentation of arrhythmia), unwitnessed deaths if the patient had been seen within 24 hours before death (in the absence of another clear cause of death), deaths caused by incessant ventricular tachyarrhythmia, deaths considered a sequel of cardiac arrest and deaths resulting from pro-arrhythmia of anti-arrhythmic drugs.31 The remainder of deaths will be classified as either non-sudden cardiovascular death, or non-cardiovascular death. Operative deaths associated with the implantation of an ICD will be counted as non-sudden cardiovascular death.

    Time frame: 2 years after randomisation

  2. Non-fatal arrhythmia

    Non-fatal arrhythmia includes resuscitated cardiac arrest, sustained ventricular tachycardia (VT) and ventricular fibrillation (VF) in participants without an ICD. Resuscitated cardiac arrest is defined as a sudden circulatory arrest requiring cardiopulmonary resuscitation (CPR) (with or without documented arrhythmia) from which the patient regains consciousness. VT and VF are defined as ECG or telemetry-documented ventricular tachycardia or ventricular fibrillation. Only sustained ventricular tachycardia will be included (greater than 30 seconds of VT) or if the VT required emergency treatment with anti-arrhythmic medications or electrical cardioversion.

    Time frame: 2 years after randomisation

Secondary outcomes

  1. All-cause mortality

    All deaths.

    Time frame: 2 years after randomisation

  2. Non-sudden cardiovascular death

    Non-sudden cardiovascular deaths will be classified as death due to myocardial infarction, heart failure or another cardiovascular cause including cerebrovascular or peripheral vascular causes.

    Time frame: 2 years after randomisation

  3. Non-fatal repeat MI

    Non-fatal repeat MI requires the presence of two of the following three: symptoms of myocardial ischaemia, a characteristic rise and fall in cardiac markers and a typical ECG pattern involving the development of Q waves or persistent T wave changes.

    Time frame: 2 years after randomisation

  4. Heart failure

    Heart failure is defined as symptoms or signs consistent with congestive heart failure with use of intravenous decongestive therapy greater than 2 hours (IV diuretics, IV nesiritide, IV inotropes) in a patient not requiring hospital admission, or, augmented heart failure regimen with oral or intravenous medications in patients requiring hospital admission.

    Time frame: 2 years after randomisation

  5. Inappropriate ICD denial

    Inappropriate ICD denial will be defined as patients who did not receive an ICD based on their intervention allocation, who went on to have documented non-fatal arrhythmia or sudden cardiac death.

    Time frame: 2 years after randomisation

  6. Appropriate ICD activations (in patients with ICD)

    Appropriate ICD activation will be defined as ventricular tachyarrhythmia due to VT which meets the treatment criteria defined above or VF.

    Time frame: 2 years after randomisation

  7. Inappropriate ICD activations (in patients with ICD)

    Inappropriate ICD activations will include supra-ventricular tachycardia, atrial fibrillation/flutter, T wave over-sensing, sinus tachycardia and noise from lead complications or extraneous noise.

    Time frame: 2 years after randomisation

  8. Complications or re-hospitalisation associated with ICD implantation (in patients with ICD)

    Complications or re-hospitalisation associated with ICD implantation (in patients with ICD)

    Time frame: 2 years after randomisation

07

Study locations

33 of 52 sites recruiting
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215, United States
    Not yet recruiting
  • Canberra Hospital
    Garran, Australian Capital Territory 2605, Australia
    Recruiting
  • Nepean Hospital
    Kingswood, New South Wales 2747, Australia
    Recruiting
  • John Hunter Hospital
    New Lambton Heights, New South Wales 2305, Australia
    Recruiting
  • Prince of Wales Hospital
    Randwick, New South Wales 2031, Australia
    Recruiting
  • Royal North Shore Hospital
    Saint Leonards, New South Wales 2065, Australia
    Recruiting
  • Westmead Hospital
    Westmead, New South Wales 2145, Australia
    Recruiting
  • Wollongong Hospital
    Wollongong, New South Wales 2500, Australia
    Recruiting
  • Sunshine Coast University Hospital
    Birtinya, Queensland 4575, Australia
    Recruiting
  • Carins Hospital
    Cairns, Queensland 4870, Australia
    Recruiting
  • The Prince Charles Hospital
    Chermside, Queensland 4032, Australia
    Recruiting
  • The Townsville Hospital
    Douglas, Queensland 4814, Australia
    Recruiting
  • Royal Brisbane and Women's Hospital
    Herston, Queensland 4029, Australia
    Recruiting
  • Gold Coast University Hospital
    Southport, Queensland 4215, Australia
    Recruiting
  • Princess Alexandra Hospital
    Woolloongabba, Queensland 4102, Australia
    Recruiting
  • Lyell McEwin Hospital
    Elizabeth Vale, South Australia 5112, Australia
    Recruiting
  • MonashHeart
    Clayton, Victoria 3168, Australia
    Completed

    Not enrolling at this site — choose another above.

  • Northern Hospital
    Epping, Victoria 3076, Australia
    Withdrawn

    Not enrolling at this site — choose another above.

  • Austin Hospital
    Melbourne, Victoria 3084, Australia
    Terminated

    Not enrolling at this site — choose another above.

  • Western Health, Sunshine and Footscray Hospitals
    Melbourne, Victoria, Australia
    Withdrawn

    Not enrolling at this site — choose another above.

  • Institute for Clinical and Experimental Medicine
    Prague, Czechia
    Not yet recruiting
  • Cardiovascular Center Bad Neustadt
    Bad Neustadt An Der Saale, Germany
    Recruiting
  • Klinikum Brandenburg
    Brandenburg, Germany
    Recruiting
  • Universitaetsmedizin Gittingen (University of Göttingen Medical Center)
    Göttingen, Germany
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Leipzig Heart Center
    Leipzig, Germany
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Universitätsklinikum Leipzig
    Leipzig, Germany
    Not yet recruiting
  • General Hospital of Athens Giorgios Gennimatas
    Athens, Greece
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • General Hospital of Athens Ippokrateio
    Athens, Greece
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • University Hospital of Heraklion Crete
    Iraklio, Greece
    Not yet recruiting
  • Semmelweis University Heart and Vascular Center
    Budapest, Hungary
    Recruiting
  • University of Debrecen
    Debrecen, Hungary
    Recruiting
  • University of Pécs
    Pécs, Hungary
    Recruiting
  • Sharee Zadek Medical Centre
    Jerusalem, Israel
    Recruiting
  • Paul Stradins University Clinic
    Riga, Latvia
    Recruiting
  • Institut Jantung Negara Sdn Bhd
    Kuala Lumpur, 50400, Malaysia
    Recruiting
  • Pusat Jantung Sarawak (PJS)(Sarawak Heart Centre)
    Kuala Lumpur, Malaysia
    Recruiting
  • Auckland City Hospital
    Grafton, Auckland 1023, New Zealand
    Withdrawn

    Not enrolling at this site — choose another above.

  • Middlemore Hospital
    Otahuhu, Auckland 2025, New Zealand
    Withdrawn

    Not enrolling at this site — choose another above.

  • Waikato Hospital
    Hamilton W., Hamilton 3204, New Zealand
    Recruiting
  • Christchurch Hospital
    Christchurch, New Zealand
    Recruiting
  • Wellington Hospital
    Wellington, 2820, New Zealand
    Recruiting
  • National Institute of Cardiology Warsaw
    Warszawa, Poland
    Not yet recruiting
  • Medical University of Łódź - Biegański Provincial Specialist Hospital
    Łódź, Poland
    Recruiting
  • Medical University of Łódź - WAM Hospital
    Łódź, Poland
    Recruiting
  • Medical University of Łódź
    Łódź, Poland
    Recruiting
  • Almazov National Medical Research Centre
    Saint Petersburg, Russian Federation
    Not yet recruiting
  • Samara State Medical University
    Samara, Russian Federation
    Withdrawn

    Not enrolling at this site — choose another above.

  • National University Heart Centre, Singapore (NUHCS)
    Singapore, 119074, Singapore
    Recruiting
  • The National Institute of Cardiovascular Diseases
    Bratislava, Slovakia
    Not yet recruiting
  • University Hospital Basel
    Basel, 4031, Switzerland
    Recruiting
  • University Hospital Bern
    Bern, 3010, Switzerland
    Recruiting
  • Lausanne University Hospital
    Lausanne, Switzerland
    Withdrawn

    Not enrolling at this site — choose another above.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2014 (actual). Primary completion is estimated for Dec 2027, 165 months after the start.

Of 47 non-industry interventional studies with no phase under Death, Sudden, Cardiac, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 86. This study's planned 165 months is above that.

Counting every sponsor, half of 56 studies reached it within 42 months; a quarter within 17 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 4, 2018
First posted
Jul 17, 2018
StartActual
Feb 27, 2014
Primary completionEst.
Dec 6, 2027
CompletionEst.
Dec 6, 2029
Last update
May 7, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 7, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03588286
Lead sponsor
Western Sydney Local Health District
Responsible party
Pramesh Kovoor (Senior Staff Specialist Cardiologist, Western Sydney Local Health District) — Principal investigator
First posted
Jul 17, 2018
Start date
Feb 27, 2014
Primary completion
Dec 6, 2027 (estimated)
Completion
Dec 6, 2029 (estimated)
Last update
May 7, 2024

Study contacts

Pramesh Kovoor
Contact
pramesh.kovoor@sydney.edu.au
+61 2 8890 6030
Anjalee T Amarasekera
Contact
Anjalee.Amarasekera@health.nsw.gov.au
+61 2 8890 4719
Study Principal Investigator Study Principal Investigator
principal investigator · Western Sydney Local Health District

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion